Skip to main content

Advertisement

SpringerLink
Log in

Update on the pathogenesis, diagnosis, and therapy of AIDs-related lymphoma

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

AIDS-related non-Hodgkin’s lymphoma (ARL) is an opportunistic malignancy that foreshortens life more than any other commonly occurring HIV-associated cancer. Treatment strategies include low-dose chemotherapy, chemotherapy given with antiretroviral therapy, and infusional chemotherapy regimens. Rituximab, an anti-CD20 monoclonal antibody, has been found to be useful in non-HIV-associated lymphomas and is of interest in ARL as well. Since the advent of highly active antiretroviral therapy, the ARL incidence and survival has changed. This paper reviews the epidemiologic, biologic, and clinical features of ARL with the aim of presenting a cohesive overview of these elements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mocroft AJ, Lundgren JD, d’Armino Monforte A, et al.: Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol 1997, 26:400–407.

    Article  PubMed  CAS  Google Scholar 

  2. Kaplan LD, Straus DJ, Testa MA, et al.: Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997, 336:1641–1648.

    Article  PubMed  CAS  Google Scholar 

  3. Dore GJ, Li Y, McDonald A, et al.: Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 2002, 29:388–395.

    PubMed  Google Scholar 

  4. Besson C, Goubar A, Gabarre J, et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001, 98:2339–2344. Provides data showing that epidemiologic changes since HAART are primarily related to changes in the CD4 cell distribution.

    Article  PubMed  CAS  Google Scholar 

  5. Karp JE, Broder S: The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention. Leuk Lymphoma 1992, 8:167–188.

    PubMed  CAS  Google Scholar 

  6. Biemer JJ: Malignant lymphomas associated with immunodeficiency states. Ann Clin Lab Sci 1990, 20:175–191.

    PubMed  CAS  Google Scholar 

  7. Gaspar B, Sharifi R, Kinnon C, et al.: Sap gene transfer restores cytotoxic function in EBV-CTLS generated from individuals with XLP. Paper presented at American Society of Hematology Annual Meeting. Orlando, FL. December 7–11, 2001.

  8. Gruhn B, Meerbach A, Häfer R, et al.: Early diagnosis and preemptive therapy of Epstein-Barr virus-associated lymphoproliferative disease following hematopoietic stem cell transplantation. Paper presented at American Society of Hematology Annual Meeting. Orlando, FL. December 7–11, 2001.

  9. Savoldo B, Gross J, Karpen S, et al.: Humanized anti-CD20 monoclonal antibody for the treatment of lymphoproliferative disease developing in pediatric solid organ transplant recipients. Paper presented at Sixth International Conference on Malignancies in AIDS & Other Immunodeficiencies: Basic, Epidemiologic & Clinical Research. Bethesda, MD. April 22–24, 2002.

  10. Liu Z, Savoldo B, Huls H, et al.: Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res 2002, 159:123–133.

    PubMed  CAS  Google Scholar 

  11. Kamel OW, van de Rijn M, Weiss LM, et al.: Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993, 328:1317–1321.

    Article  PubMed  CAS  Google Scholar 

  12. Montalban C, Manzanal A, Boixeda D, et al.: Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Ann Oncol 1997, 8(Suppl 2):37–39.

    Article  PubMed  Google Scholar 

  13. Levine AM, Shibata D, Sullivan-Halley J, et al.: Epidemiological and biological study of acquired immunodeficiency syndrome-related lymphoma in the County of Los Angeles: preliminary results. Cancer Res 1992, 52(19 Suppl):5482s-5484s.

    PubMed  CAS  Google Scholar 

  14. Knowles DM: Etiology and pathogenesis of AIDS-related non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am 1996, 10:1081–1090.

    Article  PubMed  CAS  Google Scholar 

  15. Kalter SP, Riggs SA, Cabanillas F, et al.: Aggressive non-Hodgkin’s lymphomas in immunocompromised homosexual males. Blood 1985, 66:655–659.

    PubMed  CAS  Google Scholar 

  16. Ziegler JL, Miner RC, Rosenbaum E, et al.: Outbreak of Burkitt’s-like lymphoma in homosexual men. Lancet 1982, 2:631–633.

    Article  PubMed  CAS  Google Scholar 

  17. Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organization Classification of Tumors: Pathology & Genetics: Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.

    Google Scholar 

  18. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937–1947.

    Article  PubMed  Google Scholar 

  19. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503–511.

    Article  PubMed  CAS  Google Scholar 

  20. Carbone A, Gloghini A, Larocca LM, et al.: Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virusrelated lymphomas. Blood 2001, 97:744–751. Original research showing tumor types and relationship to histogenic origins.

    Article  PubMed  CAS  Google Scholar 

  21. Schlaifer D, Brousset P, Attal M, et al.: bcl-2 Proto-oncogene and Epstein-Barr virus latent membrane protein-1 expression in AIDS-related lymphoma. Histopathology 1994, 25:77–82.

    Article  PubMed  CAS  Google Scholar 

  22. Gaidano G, Pastore C, Volpe G: Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective. Haematologica 1995, 80:454–472.

    PubMed  CAS  Google Scholar 

  23. Gascoyne RD, Adomat SA, Krajewski S, et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 1997, 90:244–251.

    PubMed  CAS  Google Scholar 

  24. Kramer MH, Hermans J, Wijburg E, et al.: Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998, 92:3152–3162.

    PubMed  CAS  Google Scholar 

  25. Gaidano G, Pastore C, Lanza C, et al.: Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. Ann Hematol 1994, 69:281–290.

    Article  PubMed  CAS  Google Scholar 

  26. Pluda JM, Venzon DJ, Tosato G, et al.: Parameters affecting the development of non-Hodgkin’s lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993, 11:1099–1107.

    PubMed  CAS  Google Scholar 

  27. Nador RG, Cesarman E, Chadburn A, et al.: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 1996, 88:645–656.

    PubMed  CAS  Google Scholar 

  28. Yawetz S, Cumberland WG, van der Meyden M, Martinez-Maza O:Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome--associated non-Hodgkin’s lymphoma. Blood 1995, 85:1843–1849.

    PubMed  CAS  Google Scholar 

  29. Widney D, Gundapp G, Said JW, et al.: Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999, 93:114–123.

    Article  PubMed  CAS  Google Scholar 

  30. Bossolasco S, Nilsson A, de Milito A, et al.: Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin’s lymphoma in the brain. AIDS 2001, 15:1109–1113.

    Article  PubMed  CAS  Google Scholar 

  31. Cote TR, Biggar RJ, Rosenberg PS, et al.: Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997, 73:645–650.

    Article  PubMed  CAS  Google Scholar 

  32. Franceschi S, Dal Maso L, La Vecchia C: Advances in the epidemiology of HIV-associated non-Hodgkin’s lymphoma and other lymphoid neoplasms. Int J Cancer 1999, 83:481–485.

    Article  PubMed  CAS  Google Scholar 

  33. Antinori A, De Rossi G, Ammassari A, et al.: Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 1999, 17:554–560. Clinically oriented research showing value of these relatively noninvasive tests for establishing diagnosis of intracerebral mass lesions.

    PubMed  CAS  Google Scholar 

  34. Centers for Disease Control: Revision of the case definition of acquired immunodeficiency syndrome for national reporting - United States. MMWR 1985, 34:373–375.

    Google Scholar 

  35. Cinque P, Brytting M, Vago L, et al.: Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 1993, 342:398–401.

    Article  PubMed  CAS  Google Scholar 

  36. Parravicini C, Chandran B, Corbellino M, et al.: Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol 2000, 156:743–749.

    PubMed  CAS  Google Scholar 

  37. Dana BW, Dahlberg S, Miller TP, et al.: m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. J Clin Oncol 1990, 8:1155–1162.

    PubMed  CAS  Google Scholar 

  38. Walsh C, Wernz JC, Levine A, et al.: Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin’s lymphoma. J Acquir Immune Defic Syndr 1993, 6:265–271.

    PubMed  CAS  Google Scholar 

  39. Levine AM, Wernz JC, Kaplan L, et al.: Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 1991, 266:84–88.

    Article  PubMed  CAS  Google Scholar 

  40. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993, 328:1002–1006.

    Article  PubMed  CAS  Google Scholar 

  41. Wilson WH: Chemotherapy for AIDS-related lymphomas [letter; comment]. N Engl J Med 1997, 337:1172–1174.

    Article  PubMed  CAS  Google Scholar 

  42. Ratner L, Redden D, Hamzeh F, et al.: Chemotherapy for HIV-NHL in combination with HAART. Paper presented at 3rd National AIDS Malignancy Meeting. Bethesda, MD. May 26–28, 1999.

  43. Antinori A, Cingolani A, Alba L, et al.: Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001, 15:1483–1491.

    Article  PubMed  CAS  Google Scholar 

  44. Levine AM, Sullivan-Halley J, Pike MC, et al.: Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991, 68:2466–2472.

    Article  PubMed  CAS  Google Scholar 

  45. Straus DJ, Huang J, Testa MA, et al.: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998, 16:3601–3606.

    PubMed  CAS  Google Scholar 

  46. Levine AM: AIDS-associated malignant lymphoma. Med Clin North Am 1992, 76:253–268.

    PubMed  CAS  Google Scholar 

  47. Vaccher E, Spina M, di Gennaro G, et al.: Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001, 91:155–163.

    Article  PubMed  CAS  Google Scholar 

  48. Ratner L, Lee J, Tang S, et al.: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001, 19:2171–2178. Clinical research showing full-dose chemotherapy with HAART is feasible.

    PubMed  CAS  Google Scholar 

  49. Spina M, Vaccher E, Juzbasic S, et al.: Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer 2001, 92:200–206.

    Article  PubMed  CAS  Google Scholar 

  50. Tirelli U, Spina M, Jaeger U, et al.: Infusional CDE with rituximab for the treatment of human immunodeficiency virusassociated non-Hodgkin’s lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res 2002, 159:149–153.

    PubMed  CAS  Google Scholar 

  51. Mackall CL, Fleisher TA, Brown MR, et al.: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994, 84:2221–2228.

    PubMed  CAS  Google Scholar 

  52. Phenix BN, Lum JJ, Nie Z, et al.: Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001, 98:1078–1085.

    Article  PubMed  CAS  Google Scholar 

  53. Mellors JW, Rinaldo CRJr, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167–1170.

    Article  PubMed  CAS  Google Scholar 

  54. Little R, Pearson D, Gutierrez M, et al.: Dose-adjusted EPOCH chemotherapy (CT) with suspension of antiretroviral therapy (ART) for HIV-associated non-Hodgkin’s lymphoma (HIVNHL). Paper presented at 4th International AIDS Malignancy Conference. Bethesda, MD. May 16–18, 2000.

  55. Raphael M, Lamine M, Abd Alsamad I, et al.: Non-Hodgkin’s lymphoma and AIDS: histopathologic features. Arch Anat Cytol Pathol 1992, 40:105–109.

    PubMed  CAS  Google Scholar 

  56. Bauer KD, Merkel DE, Winter JN, et al.: Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res 1986, 46:3173–3178.

    PubMed  CAS  Google Scholar 

  57. Miller TP, Grogan TM, Dahlberg S, et al.: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin’s lymphomas: a prospective Southwest Oncology Group trial. Blood 1994, 83:1460–1466.

    PubMed  CAS  Google Scholar 

  58. Wilson WH, Teruya-Feldstein J, Fest T, et al.: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood 1997, 89:601–609.

    PubMed  CAS  Google Scholar 

  59. Tulpule A, Sherrod A, Dharmapala D, et al.: Multidrug resistance (MDR-1) expression in aids-related lymphomas. Leuk Res 2002, 26:121–127.

    Article  PubMed  CAS  Google Scholar 

  60. Lai GM, Chen YN, Mickley LA, et al.: P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991, 49:696–703.

    Article  PubMed  CAS  Google Scholar 

  61. Vose JM, Link BK, Grossbard ML, et al.: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2001, 19:389–397.

    PubMed  CAS  Google Scholar 

  62. Mackall CL, Fleisher TA, Brown MR, et al.: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143–149.

    Article  PubMed  CAS  Google Scholar 

  63. Levine AM: Epidemiology, clinical characteristics, and management of AIDS-related lymphoma. Hematol Oncol Clin North Am 1991, 5:331–342.

    PubMed  CAS  Google Scholar 

  64. Winceslaus J: Regression of AIDS-related pleural effusion with HAART. Highly active antiretroviral therapy [letter]. Int J STD AIDS 1998, 9:368–370.

    PubMed  CAS  Google Scholar 

  65. Raez LE, Patel P, Feun L, et al.: Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 1998, 9:199–208.

    PubMed  CAS  Google Scholar 

  66. Ling SM, Roach M III, Larson DA, Wara WM: Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer 1994, 73:2570–2582.

    Article  PubMed  CAS  Google Scholar 

  67. Hoffmann C, Tabrizian S, Wolf E, et al.: Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001, 15:2119–2127.

    Article  PubMed  CAS  Google Scholar 

  68. Montesinos-Rongen M, Kuppers R, Schluter D, et al.: Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999, 155:2077–2086.

    PubMed  CAS  Google Scholar 

  69. Forsyth PA, Yahalom J, DeAngelis LM: Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994, 44:1473–1479.

    PubMed  CAS  Google Scholar 

  70. Singhal D, Witham TF, Germanwala A, et al.: Multi-modality therapy leads to longer survival in primary central nervous system lymphoma patients. Can J Neurol Sci 2002, 29:147–153.

    PubMed  Google Scholar 

  71. Jacomet C, Girard PM, Lebrette MG, et al.: Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS 1997, 11:1725–1730.

    Article  PubMed  CAS  Google Scholar 

  72. Hanel M, Fiedler F, Thorns C: Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie 2001, 24:491–494.

    Article  PubMed  CAS  Google Scholar 

  73. Little RF, Gutierrez M, Jaffe ES, et al.: HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA 2001, 285:1880–1885.

    Article  PubMed  CAS  Google Scholar 

  74. Gisselbrecht C, Oksenhendler E, Tirelli U, et al.: Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med 1993, 95:188–196.

    Article  PubMed  CAS  Google Scholar 

  75. Sparano JA, Wiernik PH, Strack M, et al.: Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin’s lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma 1994, 14:263–271.

    PubMed  CAS  Google Scholar 

  76. Little RF, Pearson D, Steinberg S, et al.: Dose-adjusted epoch chemotherapy (CT) in previously untreated HIV-associated non-Hodgkin’s lymphoma (HIV-NHL). Paper presented at American Society of Clinical Oncology 35th Annual Meeting. Atlanta. May 15–18, 1999.

  77. Ballerini P, Gaidano G, Gong J, et al.: Molecular pathogenesis of HIV-associated lymphomas. AIDS Res Hum Retroviruses 1992, 8:731–735.

    PubMed  CAS  Google Scholar 

  78. Ballerini P, Gaidano G, Gong JZ, et al.: Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma. Blood 1993, 81:166–176.

    PubMed  CAS  Google Scholar 

  79. Carbone A, Gaidano G, Gloghini A, et al.: Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virusencoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndromerelated non-Hodgkin’s lymphomas. Blood 1998, 91:747–755.

    PubMed  CAS  Google Scholar 

  80. Delecluse HJ, Raphael M, Magaud JP, et al.: Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors, I. Blood 1993, 82:552–563.

    PubMed  CAS  Google Scholar 

  81. Martin A, Flaman JM, Frebourg T, et al.: Functional analysis of the p53 protein in AIDS-related non-Hodgkin’s lymphomas and polymorphic lymphoproliferations. Br J Haematol 1998, 101:311–317.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 10S255, 10 Center Drive MSC 1868, 20892-1868, Bethesda, MD, USA

    Richard F. Little MD

Authors
  1. Richard F. Little MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wyndham H. Wilson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Little, R.F., Wilson, W.H. Update on the pathogenesis, diagnosis, and therapy of AIDs-related lymphoma. Curr Infect Dis Rep 5, 176–184 (2003). https://doi.org/10.1007/s11908-003-0055-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-003-0055-1

Keywords

Search

Navigation